On the public citation graph

Identification of SARS-CoV-2 Main Protease Inhibitors Using Chemical Similarity Analysis Combined with Machine Learning

0 signed · 99 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cmdc.202000924openalex-snapshot
A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**
inferredcites →https://doi.org/10.1002/jcc.24660openalex-snapshot
CHARMM‐GUI 10 years for biomolecular modeling and simulation
inferredcites →https://doi.org/10.1002/med.21862openalex-snapshot
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition
inferredcites →https://doi.org/10.1002/minf.201800041openalex-snapshot
Cheminformatics in Drug Discovery, an Industrial Perspective
inferredcites →https://doi.org/10.1002/minf.202000028openalex-snapshot
Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds
inferredcites →https://doi.org/10.1002/minf.202000050openalex-snapshot
A Fragment Library of Natural Products and its Comparative Chemoinformatic Characterization
inferredcites →https://doi.org/10.1002/minf.202000113openalex-snapshot
QSAR Modeling of SARS‐CoV M pro Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS‐CoV‐2
inferredcites →https://doi.org/10.1002/minf.202200198openalex-snapshot
Discovery of natural‐derived Mpro inhibitors as therapeutic candidates for COVID‐19: Structure‐based pharmacophore screening combined with QSAR analysis
inferredcites →https://doi.org/10.1007/s13318-018-0496-4openalex-snapshot
Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors
inferredcites →https://doi.org/10.1016/j.antiviral.2020.104787openalex-snapshot
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
inferredcites →https://doi.org/10.1016/j.apsb.2020.02.008openalex-snapshot
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
inferredcites →https://doi.org/10.1016/j.bcp.2008.01.005openalex-snapshot
Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus
inferredcites →https://doi.org/10.1016/j.biopha.2022.113432openalex-snapshot
Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses
inferredcites →https://doi.org/10.1016/j.bmcl.2009.06.078openalex-snapshot
Discovery of a novel protein kinase B inhibitor by structure-based virtual screening
inferredcites →https://doi.org/10.1016/j.cell.2020.03.035openalex-snapshot
A Genomic Perspective on the Origin and Emergence of SARS-CoV-2
inferredcites →https://doi.org/10.1016/j.celrep.2021.110049openalex-snapshot
Contribution of autophagy machinery factors to HCV and SARS-CoV-2 replication organelle formation
inferredcites →https://doi.org/10.1016/j.chom.2020.11.003openalex-snapshot
Integrative Imaging Reveals SARS-CoV-2 Induced Reshaping of Subcellular Morphologies
inferredcites →https://doi.org/10.1016/j.drudis.2018.01.010openalex-snapshot
Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: how far can they be simplified?
inferredcites →https://doi.org/10.1016/j.drudis.2020.01.015openalex-snapshot
Recent discovery and development of inhibitors targeting coronaviruses
inferredcites →https://doi.org/10.1016/j.ebiom.2023.104559openalex-snapshot
Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
inferredcites →https://doi.org/10.1016/j.ejmech.2016.03.085openalex-snapshot
2,3,4-Trihydroxybenzyl-hydrazide analogues as novel potent coxsackievirus B3 3C protease inhibitors
inferredcites →https://doi.org/10.1016/j.ijsu.2020.10.018openalex-snapshot
Ebselen, a new candidate therapeutic against SARS-CoV-2
inferredcites →https://doi.org/10.1016/j.jcv.2004.03.003openalex-snapshot
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
inferredcites →https://doi.org/10.1016/j.jiph.2023.09.020openalex-snapshot
Exploring the structural and molecular interaction landscape of nirmatrelvir and Mpro complex: The study might assist in designing more potent antivirals targeting SARS-CoV-2 and other viruses
inferredcites →https://doi.org/10.1016/j.jsb.2020.107690openalex-snapshot
Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2
inferredcites →https://doi.org/10.1016/j.pharep.2019.02.011openalex-snapshot
Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug
inferredcites →https://doi.org/10.1016/j.tim.2020.12.007openalex-snapshot
Dysregulation of Cell Signaling by SARS-CoV-2
inferredcites →https://doi.org/10.1016/s0140-6736(20)30304-4openalex-snapshot
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
inferredcites →https://doi.org/10.1021/acs.jcim.1c00263openalex-snapshot
Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro
inferredcites →https://doi.org/10.1021/acs.jcim.1c00683openalex-snapshot
Machine Learning Models Identify Inhibitors of SARS-CoV-2
inferredcites →https://doi.org/10.1021/acs.jcim.3c00324openalex-snapshot
Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2
inferredcites →https://doi.org/10.1021/acs.jmedchem.0c01140openalex-snapshot
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b00104openalex-snapshot
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
inferredcites →https://doi.org/10.1021/acsinfecdis.2c00091openalex-snapshot
Pyronaridine Protects against SARS-CoV-2 Infection in Mouse
inferredcites →https://doi.org/10.1021/acsomega.0c04808openalex-snapshot
Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease
inferredcites →https://doi.org/10.1021/acsomega.2c02794openalex-snapshot
Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice
inferredcites →https://doi.org/10.1021/acsptsci.0c00130openalex-snapshot
Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV‑2 Main Protease Inhibitors
inferredcites →https://doi.org/10.1021/acsptsci.0c00216openalex-snapshot
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
inferredcites →https://doi.org/10.1021/ar500432kopenalex-snapshot
The Chemical Space Project
inferredcites →https://doi.org/10.1021/ci00062a008openalex-snapshot
SMILES. 2. Algorithm for generation of unique SMILES notation
inferredcites →https://doi.org/10.1021/ci010132ropenalex-snapshot
Reoptimization of MDL Keys for Use in Drug Discovery
inferredcites →https://doi.org/10.1021/ci100050topenalex-snapshot
Extended-Connectivity Fingerprints
inferredcites →https://doi.org/10.1038/nmeth.4067openalex-snapshot
CHARMM36m: an improved force field for folded and intrinsically disordered proteins
inferredcites →https://doi.org/10.1038/s41392-023-01392-wopenalex-snapshot
A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants
inferredcites →https://doi.org/10.1038/s41401-020-0483-6openalex-snapshot
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients
inferredcites →https://doi.org/10.1038/s41422-020-0282-0openalex-snapshot
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
inferredcites →https://doi.org/10.1038/s41467-020-18096-2openalex-snapshot
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
inferredcites →https://doi.org/10.1038/s41467-022-31210-wopenalex-snapshot
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance
inferredcites →https://doi.org/10.1038/s41573-023-00692-8openalex-snapshot
Accelerating antiviral drug discovery: lessons from COVID-19
inferredcites →https://doi.org/10.1038/s41586-020-2223-yopenalex-snapshot
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
inferredcites →https://doi.org/10.1038/s41597-023-01984-9openalex-snapshot
SARS-CoV2 billion-compound docking
inferredcites →https://doi.org/10.1038/s42003-020-01577-xopenalex-snapshot
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
inferredcites →https://doi.org/10.1038/srep42717openalex-snapshot
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
inferredcites →https://doi.org/10.1039/d0cs01065kopenalex-snapshot
A critical overview of computational approaches employed for COVID-19 drug discovery
inferredcites →https://doi.org/10.1039/d0md00367kopenalex-snapshot
Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
inferredcites →https://doi.org/10.1039/d2dd00030jopenalex-snapshot
Chemical space: limits, evolution and modelling of an object bigger than our universal library
inferredcites →https://doi.org/10.1073/pnas.2003138117openalex-snapshot
Cell entry mechanisms of SARS-CoV-2
inferredcites →https://doi.org/10.1073/pnas.2117142119openalex-snapshot
Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2
inferredcites →https://doi.org/10.1080/07391102.2023.2193994openalex-snapshot
Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease
inferredcites →https://doi.org/10.1080/07391102.2023.2245474openalex-snapshot
A novel robust inhibitor of papain-like protease (PLpro) as a COVID-19 drug
inferredcites →https://doi.org/10.1093/cid/ciac933openalex-snapshot
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
inferredcites →https://doi.org/10.1101/2020.07.28.223784openalex-snapshot
A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors
inferredcites →https://doi.org/10.1111/cbdd.14187openalex-snapshot
Combining computational and experimental evidence on the activity of antimalarial drugs on papain‐like protease of SARS‐CoV ‐2: A repurposing study
inferredcites →https://doi.org/10.1126/sciadv.abd0345openalex-snapshot
Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease
inferredcites →https://doi.org/10.1126/science.abb3405openalex-snapshot
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
inferredcites →https://doi.org/10.1128/aac.00872-20openalex-snapshot
Discovery of M Protease Inhibitors Encoded by SARS-CoV-2
inferredcites →https://doi.org/10.1128/aac.02577-20openalex-snapshot
Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2
inferredcites →https://doi.org/10.1128/aac.03036-14openalex-snapshot
Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
inferredcites →https://doi.org/10.1128/jvi.01819-20openalex-snapshot
A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL pro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19
inferredcites →https://doi.org/10.1128/mbio.00869-22openalex-snapshot
Genetic Surveillance of SARS-CoV-2 M pro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
inferredcites →https://doi.org/10.1159/000519564openalex-snapshot
Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases
inferredcites →https://doi.org/10.1371/journal.pone.0194868openalex-snapshot
MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells
inferredcites →https://doi.org/10.1586/14787210.4.2.291openalex-snapshot
Potential antivirals and antiviral strategies against SARS coronavirus infections
inferredcites →https://doi.org/10.2174/1381612822666151125000550openalex-snapshot
Computer Aided Drug Design: Success and Limitations
inferredcites →https://doi.org/10.2174/1570163817666200316104404openalex-snapshot
An Analysis of QSAR Research Based on Machine Learning Concepts
inferredcites →https://doi.org/10.2174/2667387816666220426133555openalex-snapshot
A Review of Computational Approaches Targeting SARS-CoV-2 Main Protease to the Discovery of New Potential Antiviral Compounds
inferredcites →https://doi.org/10.3389/fddsv.2021.728551openalex-snapshot
Grand Challenges of Computer-Aided Drug Design: The Road Ahead
inferredcites →https://doi.org/10.3389/fddsv.2023.1261094openalex-snapshot
Consensus docking aid to model the activity of an inhibitor of DNA methyltransferase 1 inspired by de novo design
inferredcites →https://doi.org/10.3389/fpubh.2022.1009393openalex-snapshot
COVID-19 outbreak: Impact on global economy
inferredcites →https://doi.org/10.3390/antib11030057openalex-snapshot
In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library
inferredcites →https://doi.org/10.3390/ijms232214189openalex-snapshot
Interaction of Masitinib with Organic Cation Transporters
inferredcites →https://doi.org/10.3390/jcm9041225openalex-snapshot
The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control
inferredcites →https://doi.org/10.3390/molecules25245808openalex-snapshot
Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CLpro) Non-Covalent Small-Molecule Inhibitors
inferredcites →https://doi.org/10.3390/molecules26103003openalex-snapshot
Prioritisation of Compounds for 3CLpro Inhibitor Development on SARS-CoV-2 Variants
inferredcites →https://doi.org/10.3390/molecules28186643openalex-snapshot
Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity
inferredcites →https://doi.org/10.3390/pharmaceutics14010176openalex-snapshot
Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets
inferredcites →https://doi.org/10.3390/v10120721openalex-snapshot
Development of Small-Molecule MERS-CoV Inhibitors
inferredcites →https://doi.org/10.3390/v13040609openalex-snapshot
Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1007/s11172-025-4579-5openalex-snapshot
Prediction of the small molecule selectivity index against influenza virus strain A/H1N1 using machine learning methods
inferred← citeshttps://doi.org/10.1016/j.bmc.2025.118426openalex-snapshot
Machine learning in antiviral drug design
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2025.111046openalex-snapshot
Nanoparticles and bioactive materials against COVID-19 and its variants: Hints from a computational-materials design perspective
inferred← citeshttps://doi.org/10.1016/j.drudis.2026.104616openalex-snapshot
Hit identification in ultra large virtual screening: an integrative review and future challenges
inferred← citeshttps://doi.org/10.1016/j.drudis.2026.104648openalex-snapshot
Can artificial intelligence transform antiviral drug discovery?
inferred← citeshttps://doi.org/10.1016/j.pep.2025.106811openalex-snapshot
A magnetic bead-based fluorescent substrate for sensitive assay of SARS-CoV-2 3C-like protease activity
inferred← citeshttps://doi.org/10.1016/j.pscia.2024.100050openalex-snapshot
Natural product databases for drug discovery: Features and applications
inferred← citeshttps://doi.org/10.1021/acs.jcim.3c01439openalex-snapshot
Consensus Pharmacophore Strategy For Identifying Novel SARS-Cov-2 Mpro Inhibitors from Large Chemical Libraries
inferred← citeshttps://doi.org/10.1038/s41598-025-02773-7openalex-snapshot
Drug repurposing targeting COVID-19 3CL protease using molecular docking and machine learning regression approaches
inferred← citeshttps://doi.org/10.1039/9781837070206-00186openalex-snapshot
Machine Learning in Ligand-based Drug Design
inferred← citeshttps://doi.org/10.1080/17460441.2025.2558161openalex-snapshot
Exploiting PubChem and other public databases for virtual screening in 2025: what are the latest trends?
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.